Results 31 to 40 of about 91,755 (270)

Nivolumab-associated acute glomerulonephritis: Case report and literature review

open access: yes, 2016
<p><strong>Background:</strong> Immune checkpoint inhibitors are changing the landscape of oncologic treatment as they are significantly improving treatment of multiple malignancies.
Xu Zeng, M.D., Ph.D.   +5 more
core   +1 more source

Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy

open access: yesAdvances in Radiation Oncology, 2018
Purpose: Radiation therapy (RT) and nivolumab are standard therapies for a wide range of advanced and metastatic cancers, yet little is known about the toxicity profile of their combined treatment.
Neha P. Amin, MD   +4 more
doaj   +1 more source

Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study

open access: yesJournal for ImmunoTherapy of Cancer
Background CheckMate 8KX was a phase I/II study investigating the pharmacokinetics and safety of subcutaneous (SC) nivolumab±recombinant human hyaluronidase PH20 (rHuPH20).Methods Patients with advanced solid tumors who were immune-checkpoint inhibitor ...
Sara Lonardi   +20 more
doaj   +1 more source

Nivolumab Efficacy and Safety in Cancer Patients with Renal Dysfunction [PDF]

open access: yes
Aim: Immune checkpoint inhibitors have transformed cancer treatment; however, clinical trials often exclude patients with renal dysfunction. This study aimed to evaluate the efficacy and safety of nivolumab in this population, addressing the limited ...
Gulcin Sahingoz Erdal   +7 more
core   +1 more source

Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States

open access: yesExperimental Hematology & Oncology, 2018
Background We evaluated the cost-effectiveness of nivolumab versus everolimus in patients with advanced renal cell carcinoma (RCC) from a US payer perspective.
Charles McCrea   +3 more
doaj   +1 more source

AEC with nivolumab

open access: yes, 2023
clinical course in AEC patients treated with ...
Naoki Takegawa (10148882)
core   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047

open access: yesJournal for ImmunoTherapy of Cancer
Background Treatment-free survival (TFS; time spent free of systemic anticancer therapy) is increasingly used to support traditional endpoints. TFS was previously evaluated in patients with advanced melanoma treated with nivolumab plus ipilimumab.
Christopher D Lao   +8 more
doaj   +1 more source

Dactolisib outperforms Rapamycin in potentiating apoptosis induced by XPO1, Bcl‐2 and Mcl‐1 blockade in preclinical glioblastoma models

open access: yesFEBS Open Bio, EarlyView.
The PAM pathway and its impact on cellular metabolism. Color‐coded key symbols represent Rapamycin (R, orange, targeting mTOR) and Dactolisib (D, green, targeting PI3K/mTOR), indicating their sites of action. Created with BioRenders.com. Glioblastoma resists therapy through interconnected survival programs.
Kai Zhao   +23 more
wiley   +1 more source

Nivolumab-induced sensory ganglionopathy

open access: yes, 2023
Introduction Nivolumab is s a human monoclonal antibody. Due to its widespread use in many cancers, including Merkel cell carcinoma, adverse reactions associated with nivolumab, such as neuropathies, endocrinopathies, gastrointestinal problems, and skin ...
Coşkun, Özlem   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy